Cargando…
Artesunate shows potent anti-tumor activity in B-cell lymphoma
BACKGROUND: Although chemo-immunotherapy has led to an improved overall survival for most B-cell lymphoma types, relapsed and refractory disease remains a challenge. The malaria drug artesunate has previously been identified as a growth suppressor in some cancer types and was tested as a new treatme...
Autores principales: | Våtsveen, Thea Kristin, Myhre, Marit Renée, Steen, Chloé Beate, Wälchli, Sébastien, Lingjærde, Ole Christian, Bai, Baoyan, Dillard, Pierre, Theodossiou, Theodossis A., Holien, Toril, Sundan, Anders, Inderberg, Else Marit, Smeland, Erlend B., Myklebust, June Helen, Oksvold, Morten P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5819282/ https://www.ncbi.nlm.nih.gov/pubmed/29458389 http://dx.doi.org/10.1186/s13045-018-0561-0 |
Ejemplares similares
-
NK cells specifically TCR-dressed to kill cancer cells
por: Mensali, Nadia, et al.
Publicado: (2019) -
Combinatorial CAR design improves target restriction
por: Köksal, Hakan, et al.
Publicado: (2020) -
Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019) -
Correction to: Preclinical assessment of transiently TCR redirected T cells for solid tumour immunotherapy
por: Mensali, Nadia, et al.
Publicado: (2019) -
Antigen-delivery through invariant chain (CD74) boosts CD8 and CD4 T cell immunity
por: Mensali, Nadia, et al.
Publicado: (2019)